Fazeel M Siddiqui1, Carl D Langefeld2, Charles J Moomaw2, Mary E Comeau2, Padmini Sekar2, Jonathan Rosand2, Chelsea S Kidwell2, Sharyl Martini2, Jennifer L Osborne2, Sonja Stutzman2, Christiana Hall2, Daniel Woo2. 1. From the Department of Neurology, Southern Illinois University School of Medicine, Springfield (F.M.S.); Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest University, Winston-Salem, NC (C.D.L., M.E.C.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (C.J.M., P.S., J.L.O., D.W.); Center for Genomic Medicine, Massachusetts General Hospital, Boston (J.R.); Departments of Neurology and Medical Imaging, University of Arizona, Tucson (C.S.K.); Michael E. DeBakey VA Medical Center and Department of Neurology, Baylor College of Medicine, Houston, TX (S.M.); and Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas (S.S., C.H.). fazeelmukhtar@gmail.com. 2. From the Department of Neurology, Southern Illinois University School of Medicine, Springfield (F.M.S.); Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest University, Winston-Salem, NC (C.D.L., M.E.C.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (C.J.M., P.S., J.L.O., D.W.); Center for Genomic Medicine, Massachusetts General Hospital, Boston (J.R.); Departments of Neurology and Medical Imaging, University of Arizona, Tucson (C.S.K.); Michael E. DeBakey VA Medical Center and Department of Neurology, Baylor College of Medicine, Houston, TX (S.M.); and Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas (S.S., C.H.).
Abstract
BACKGROUND AND PURPOSE: Statin use may be associated with improved outcome in intracerebral hemorrhage patients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. METHODS: We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). RESULTS: Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42% females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. CONCLUSIONS: Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.
BACKGROUND AND PURPOSE: Statin use may be associated with improved outcome in intracerebral hemorrhagepatients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. METHODS: We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). RESULTS: Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42% females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. CONCLUSIONS: Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.
Authors: Dar Dowlatshahi; Andrew M Demchuk; Jiming Fang; Moira K Kapral; Mukul Sharma; Eric E Smith Journal: Stroke Date: 2012-03-22 Impact factor: 7.914
Authors: Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo Journal: Stroke Date: 2010-07-22 Impact factor: 7.914
Authors: José María Ramírez-Moreno; Ignacio Casado-Naranjo; Juan Carlos Portilla; María Luisa Calle; David Tena; Alfonso Falcón; Ana Serrano Journal: Stroke Date: 2009-03-19 Impact factor: 7.914
Authors: Dongmei Yang; Robert A Knight; Yuxia Han; Kishor Karki; Jianfeng Zhang; Michael Chopp; Donald M Seyfried Journal: J Behav Brain Sci Date: 2012-12-10
Authors: Cora H Ormseth; Guido J Falcone; Sara D Jasak; David M Mampre; Audrey C Leasure; Laura C Miyares; David Y Hwang; Michael L James; Fernando D Testai; Kyra J Becker; David L Tirschwell; Carl D Langefeld; Daniel Woo; Kevin N Sheth Journal: Neurocrit Care Date: 2018-12 Impact factor: 3.210
Authors: Ching-Jen Chen; Dale Ding; Natasha Ironside; Thomas J Buell; Lori J Elder; Amy Warren; Amy P Adams; Sarah J Ratcliffe; Robert F James; Neeraj S Naval; Bradford B Worrall; Karen C Johnston; Andrew M Southerland Journal: Neurology Date: 2019-11-11 Impact factor: 9.910
Authors: Jakob I Doerrfuss; Azmil H Abdul-Rahim; Bob Siegerink; Christian H Nolte; Kennedy R Lees; Matthias Endres; Scott E Kasner; Jan F Scheitz Journal: Eur Stroke J Date: 2019-11-25
Authors: Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding Journal: Neurocrit Care Date: 2021-08-02 Impact factor: 3.210
Authors: Ruxandra-Nicoleta Horodinschi; Ana Maria Alexandra Stanescu; Ovidiu Gabriel Bratu; Anca Pantea Stoian; Daniel George Radavoi; Camelia Cristina Diaconu Journal: Medicina (Kaunas) Date: 2019-10-30 Impact factor: 2.430